Reference data : LOINC code

Filter


Clear filter

Results
104,672 results found
Loinc Number Component Property System Time aspect ScaleType MethodType Relat_nms loincStatus Long Common name answerList chngType DefinitionDescription dtLastCh exactCmspy exampleUnits exmplAnswers externalCopyrightNotice formula hl7FieldSubfieldId InpcPercentage ipccUnits loincClass loincFinal loincNum mapTo methodTyp molarMass naaccrId orderObs panelElements reference scope setRoot shortName source surveyQuestSrc surveyQuestText unitsRequired acssym relatedNames2 VersionLastChanged VersionFirstRelease ValidHL7AttachmentRequest PanelType AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
40442-6 Heart rate^post exercise NRat XXX Pt Qn     ACTIVE Heart rate --post exercise   MIN DefinitionDescription     beats/min             HRTRATE.MOLEC   40442-6                 0 Heart rate p Exc       N   After; Count/time; EXCZ; Heart beat; HEART RATE.MOLEC; Misc; Miscellaneous; nRate; Number rate; Number Rate = Count/Time; Other; p Exc; Point in time; PST; Pulse; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified 2.73 2.15               {beats}/min       0
40443-4 Heart rate^resting NRat XXX Pt Qn     ACTIVE Heart rate --resting   MIN DefinitionDescription     beats/min             HRTRATE.MOLEC   40443-4                 0 Heart rate Resting       N   Count/time; Heart beat; HEART RATE.MOLEC; Misc; Miscellaneous; nRate; Number rate; Number Rate = Count/Time; Other; Point in time; Pulse; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified 2.42 2.15               {beats}/min       0
40444-2 Cytomegalovirus gene mutations detected Prid Isolate Pt Nom     ACTIVE CMV gene mutations detected [Identifier]   MIN DefinitionDescription       Gancyclovir resistant - ED50 = 5.5mmol           ABXBACT   40444-2         Both       0 CMV gene Mut Det Islt       N   ANTIBIOTIC SUSCEPTIBILITIES; CMV; CMV gene; Cytomegalo virus; Cytomgal; HHV-5; Human Herpesvirus-5; ID; Identity or presence; Infectious Disease; InfectiousDisease; Islt; Isol; Mut; Mut Det; Mutation; Muts; Nominal; Point in time; Random 2.73 2.15                       0
40445-9 Gas delivery source^resting Type Respiratory system Pt Nom     ACTIVE Gas delivery source Respiratory system --resting   MIN DefinitionDescription                   PULM   40445-9                 0 Gas deliv source Resting Respiratory       N   Breathing; Gas deliv source; Gases; Lung; Lungs; Nominal; Point in time; PULMONARY; Pulmonology; Random; Respiratory; RS; Srce; Typ 2.29 2.15                       0
40446-7 Gas delivery source^post exercise Type Respiratory system Pt Nom     ACTIVE Gas delivery source Respiratory system --post exercise   MIN DefinitionDescription                   CLIN   40446-7                 0 Gas deliv source p Exc Respiratory       N   After; Breathing; CLIN; EXCZ; Gas deliv source; Gases; Lungs; Nominal; p Exc; Point in time; PST; Random; RS; Srce; Typ 2.29 2.15                       0
40447-5 Gas flow.oxygen^resting VRat Oxygen delivery system Pt Qn     ACTIVE Oxygen gas flow Oxygen delivery system --resting   MIN DefinitionDescription                   PULM   40447-5                 0 Gas flow.O2 Resting O2 delivery sys       N   Dynamic; Flow; Gas flow.O2; Gases; Lung; O2; O2 delivery sys; Point in time; PULMONARY; Pulmonology; QNT; Quan; Quant; Quantitative; Random; Respiratory; tO2; Volume rate; vRate 2.4 2.15               L/min       0
40448-3 Gas flow.oxygen^post exercise VRat Oxygen delivery system Pt Qn     ACTIVE Oxygen gas flow Oxygen delivery system --post exercise   MIN DefinitionDescription                   PULM   40448-3                 0 Gas flow.O2 p Exc O2 delivery sys       N   After; Dynamic; EXCZ; Flow; Gas flow.O2; Gases; Lung; O2; O2 delivery sys; p Exc; Point in time; PST; Pulmonary; Pulmonology; QNT; Quan; Quant; Quantitative; Random; Respiratory; tO2; Volume rate; vRate 2.4 2.15               L/min       0
40449-1 Oxygen saturation^resting MFr BldC Pt Qn Oximetry   DEPRECATED Deprecated Oxygen saturation in Capillary blood by Oximetry --resting   DEL DefinitionDescription     %             HEMODYN.MOLEC   40449-1   Oximetry             0 Deprecated SaO2% Resting BldC Oximetry       N   Blood - capillary; Cap bld; Cap blood; Capillary bld; Capillary blood; Finger stick; Hemodynamics; HEMODYNAMICS.MOLEC; Mass Fraction; O2; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; SaO2; SAT; Satn; SO2; tO2 2.36 2.15       AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
4045-1 Tetracycline MCnc Ser/Plas Pt Qn     ACTIVE Tetracycline [Mass/volume] in Serum or Plasma   MIN DefinitionDescription     ug/mL             DRUG/TOX   4045-1         Both       0 Tetracycline SerPl-mCnc       Y   Achromycin V; C18; c211; C75; Chemiciclina; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Panmycin; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tetrabioptal 2.73 1               ug/mL       0
40450-9 Oxygen saturation^post exercise MFr BldC Pt Qn Oximetry   DEPRECATED Deprecated Oxygen saturation in Capillary blood by Oximetry --post exercise   DEL DefinitionDescription     %             HEMODYN.MOLEC   40450-9   Oximetry             0 Deprecated SaO2% p Exc BldC Oximetry       N   After; Blood - capillary; Cap bld; Cap blood; Capillary bld; Capillary blood; EXCZ; Finger stick; Hemodynamics; HEMODYNAMICS.MOLEC; Mass Fraction; O2; p Exc; Percent; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SaO2; SAT; Satn; SO2; tO2 2.36 2.15       AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
40451-7 Lead PrThr Stool Pt Ord     ACTIVE Lead [Presence] in Stool   MIN DefinitionDescription       Not detected           DRUG/TOX   40451-7         Both       0 Lead Stl Ql       N   Bowel movement; DRUG/TOXICOLOGY; Drugs; Faecal; Faeces; Fecal; Feces; Ordinal; Painter's colic; PB; Plumbism; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Stl; Stool = Fecal 2.56 2.15                     The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
40452-5 Sialate/Creatinine Ratio Urine Pt Qn     ACTIVE Sialate/Creatinine [Ratio] in Urine   MIN DefinitionDescription     nmol/mg creatinine             CHEM   40452-5         Both       0 Sialate/Creat Ur-Rto       N   Chemistry; CR; Crea; Creat; N-Acetylneuraminic Acid; Point in time; QNT; Quan; Quant; Quantitative; Random; Ratios; Rto; SA; Sialic acid; UA; UCr; UR; Urn 2.7 2.15               nmol/mg{creat}       0
40453-3 Sialooligosaccharides PrThr Urine Pt Ord     ACTIVE Sialooligosaccharides [Presence] in Urine   MIN DefinitionDescription       Positive/Negative           CHEM   40453-3         Both       0 Sialooligosacch Ur Ql       N   Chemistry; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn 2.56 2.15                     Changed answer list from "Normative" to "Example" to fit the current LOINC model.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
40454-1 Coagulum lysis PrThr PPP Pt Ord Coag   ACTIVE Clot Lysis [Presence] in Platelet poor plasma by Coagulation assay   MIN DefinitionDescription       Positive/Negative           COAG   40454-1   Coag     Both       0 Clot Lysis PPP Ql       N   Clot; Clot firmness reduction; Clot Lysis; Clottable; COAGULATION; Coagulation assay; Eug; Euglobulin clot lysis time; Hematology; Heme; Ordinal; Plas; Platelet poor plasma; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tilt tube 2.73 2.15                     The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; Updated Answer list type from NORMATIVE to EXAMPLE because the Answers in the list (Positive, Negative) are only examples of possible answers and not an exclusive list 0
40455-8 Ceruloplasmin actual/Normal RelMCnc Ser/Plas Pt Qn     ACTIVE Ceruloplasmin actual/normal in Serum or Plasma   MIN DefinitionDescription     % normal             CHEM   40455-8         Observation       0 Ceruloplasmin Act/Nor SerPl       N   Act/Nor; Caeruloplasmin; Chemistry; Control; Copper oxidase; Cp; Ferroxidase; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Relative mass concentration; RLMCNC; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.7 2.15               %       0
40456-6 Beta 2 glycoprotein 1 Ab ACnc Ser Pt Qn     ACTIVE Beta 2 glycoprotein 1 Ab [Units/volume] in Serum   MIN DefinitionDescription     arb U/mL             COAG   40456-6         Both       0 B2 Glycoprot1 Ab Ser-aCnc       N   ABS; Aby; Antby; Anti; Antibodies; Antibody; APOH; Apolipoprotein H; Arbitrary concentration; Autoantibodies; Autoantibody; B; B2 Glycoprot1; B2 glycoprotein 1; B2GPI; B2-GPI; COAGULATION; gG; Glycoprot; Glycoproteins; GP; Hematology; Heme; i; II; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR 2.73 2.15               [arb'U]/mL       0
40457-4 Prothrombin Ab ACnc Ser/Plas Pt Qn     ACTIVE Prothrombin Ab [Units/volume] in Serum or Plasma   MIN DefinitionDescription     arb U/mL             COAG   40457-4         Both       0 Prothrom Ab SerPl-aCnc       N   ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; COAGULATION; Coagulation factor II; Factor 2; Factor II; Hematology; Heme; Pl; Plasma; Plsm; Point in time; Prothombin; Prothrm; Prothromb; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.73 2.15               [arb'U]/mL       0
40458-2 Coagulation tissue factor induced.factor substitution^immediately after addition of factor VIII depleted plasma Time PPP Pt Qn Coag   ACTIVE Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of factor VIII depleted plasma   MIN DefinitionDescription     s             COAG   40458-2   Coag     Observation       0 PT imm FVIII DP PPP       N   Clot; Clottable; Coag; Coagulation assay; F8; Fac; Fact; Fact VIII; Factor 8; FVIII; Hematology; Heme; imm FVIII DP; Immediatedly after 1:1 addition of; Mixing studies; Plas; Platelet poor plasma; Point in time; Pro time; Prothrombin time; Protime; PT; PT correction study; PT immediate mix; PT incubated mix; QNT; Quan; Quant; Quantitative; Random; Tilt tube 2.44 2.15               s       0
40459-0 Hepatitis B virus DNA LnCnc Ser Pt Qn Probe.amp.sig   ACTIVE Hepatitis B virus DNA [Log #/volume] (viral load) in Serum by Probe with signal amplification   MIN DefinitionDescription     log copies/mL             MICRO   40459-0   Probe.amp.sig     Both       0 HBV DNA Ser Probe+sig amp-Log#       N   Amplif; Amplification; Amplified; bDNA; Bdn-A; Branched Chain DNA; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HBV; HC; Hep; Hep B; Hepatis; Hepatit; Hepatology; HepB; HPA; Hybidization Protection Assay; Hybrid Capture; Hybrid Capture nucleic acid hybridization; ID; Infectious Disease; InfectiousDisease; Liver; Log NCNC; Log#; Microbiology; Point in time; Probe amp; Probe with ampification; Probe with signal amplification; Probe+sig amp; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Viral load 2.73 2.15               {Log_copies}/mL       0
4046-9 Tetrahydrocortisone MCnc Urine Pt Qn     ACTIVE Tetrahydrocortisone [Mass/volume] in Urine   MIN DefinitionDescription     mg/dL             DRUG/TOX   4046-9         Both       0 THcortisone Ur-mCnc       Y   DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; THcortisone; UA; UR; Urn 2.42 1               mg/dL       0
40460-8 Phenytoin.bound MCnc Ser/Plas Pt Qn     ACTIVE Phenytoin.bound [Mass/volume] in Serum or Plasma   MIN DefinitionDescription     ug/mL             DRUG/TOX   40460-8         Both       0 Bnd Phenytoin SerPl-mCnc       N   Associated; bnd; Bnd Phenytoin; DI-HYDAN; Dilantin; Dilj; Diphenylhydantoin; DPH; DRUG/TOXICOLOGY; Drugs; Epanutin; Fenantoin; Lehydan; Level; Mass concentration; Phenhydan; PHYT; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sinergina; SR; Zentropil 2.73 2.15               ug/mL       0
40461-6 GJB1 gene allele 1 Prid Bld/Tiss Pt Nom Molgen   ACTIVE GJB1 gene allele 1 [Identifier] in Blood or Tissue by Molecular genetics method Nominal   MIN DefinitionDescription       Normal           MOLPATH.MUT   40461-6   Molgen     Observation       0 GJB1 allele 1 Bld/T       N   Blood; Charcot-Marie-Tooth neuropathy, X-linked; CMTX; CMTX1; Connexin 32; CX32; gap junction protein, beta 1, 32kDa; Genetics; GJB1 allele 1; Heredity; Heritable; i; Identity or presence; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Nominal; PCR; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue 2.15 2.15                       0
40462-4 GJB1 gene allele 2 Prid Bld/Tiss Pt Nom Molgen   ACTIVE GJB1 gene allele 2 [Identifier] in Blood or Tissue by Molecular genetics method Nominal   MIN DefinitionDescription       Normal           MOLPATH.MUT   40462-4   Molgen     Observation       0 GJB1 allele 2 Bld/T       N   Blood; Charcot-Marie-Tooth neuropathy, X-linked; CMTX; CMTX1; Connexin 32; CX32; gap junction protein, beta 1, 32kDa; Genetics; GJB1 allele 2; Heredity; Heritable; Identity or presence; II; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Nominal; PCR; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue 2.15 2.15                       0
40463-2 TNFRSF1A gene targeted mutation analysis Find Bld/Tiss Pt Doc Molgen   ACTIVE TNFRSF1A gene targeted mutation analysis in Blood or Tissue by Molecular genetics method   MIN DefinitionDescription       MUTATION ANALYSIS: ANALYSIS PROCEEDED ON GENOMIC DNA OBTAINED FROM THE SUBMITTED SAMPLE. COMPLETE BI-DIRECTIONAL SEQUENCE OF EXONS 2, 3, 4, AND 5, INTRON 2, INTRON 4 AND THE INTRON/EXON JUNCTIONS OF THE TNFRSF1A GENE WERE ANALYZED. RESULT: THERE WERE NO DISEASE-ASSOCIATED CHANGES IN DNA SEQUENCE IDENTIFIED IN THE PATIENT SAMPLE AS COMPARED TO THE PUBLISHED GENOMIC DNA SEQUENCE OF THE TNFRSF1A GENE. HETEROZYGOSITY WAS OBSERVED AT A POLYMORPHIC POSITION WITHIN AN INTRON (IVS4-33C/T). THIS FINDING IS RELATIVELY COMMON IN THE GENERAL POPULATION AND IS OF NO KNOWN CLINICAL SIGNIFICANCE. INTERPRETATION: NO SEQUENCE CHANGE CONSISTENT WITH THE CLINICAL DIAGNOSIS OF TRAPS WAS IDENTIFIED. THE ANALYSIS PERFORMED HERE WOULD NOT DETECT MUTATIONS IN EXONS OTHER THAN 2, 3, 4, OR 5, OR FURTHER INTO THE INTRON SEQUENCE. HOWEVER, TO DATE, NO DISEASE-ASSICIATED CHANGES IN THOSE REGIONS OF THE TNFRSF1A GENE HAVE BEEN FOUND IN TRAPS PATIENTS. IF CONSISTENT WITH CLINICAL PRESENTATION AND FAMILY HISTORY, MUTATION ANALYSIS OF THE MEFV GENE IN FAMILIAL MEDITERRANEAN FEVER AND/OF THE MVK GENE IN HYPER-IGD SYNDROME COULD BE CONSIDERED.           MOLPATH.MUT   40463-2   Molgen     Both       0 TNFRSF1A gene Mut Anl Bld/T       N   Blood; CD120a; CD120a gene; Document; Finding; Findings; FPF; Genetics; Heredity; Heritable; Inherited; MGC19588; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MS5; Mut; Mut Anl; Mutations; p55; p55-R; p60; PCR; Point in time; Random; TBP1; Tissue; Tissue, unspecified; TNFAR; TNF-R; TNFR1; TNFR1-d2; TNFR55; TNF-R55; TNFR60; TNF-R-I; TRAPS; Tumor necrosis factor associated periodic syndrome; Tumor necrosis factor binding protein 1 gene; Tumor necrosis factor receptor superfamily, member 1A; Tumor necrosis factor receptor type 1; Tumor necrosis factor-alpha receptor; WB; Whole blood; Whole blood or Tissue 2.68 2.15                     Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. 0
40464-0 Drugs Prid Urine Pt Nom Confirm   ACTIVE Drugs identified in Urine by Confirmatory method   NAM DefinitionDescription                   DRUG/TOX   40464-0   Confirm     Both       0 Drugs Ur Cfm       N   Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Drug; DRUG/TOXICOLOGY; Drugs; GCMS; Identity or presence; LC/MS/MS; Nominal; Point in time; Random; UA; UniversalLabOrders; UR; Urn 2.79 2.15                     Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; 0
104,672 results found